Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma

Abstract Background Medulloblastoma (MB) is the most common malignant paediatric brain tumour and a leading cause of cancer-related mortality and morbidity. Existing treatment protocols are aggressive in nature resulting in significant neurological, intellectual and physical disabilities for the chi...

Full description

Bibliographic Details
Main Authors: Laura A. Genovesi, Amanda Millar, Elissa Tolson, Matthew Singleton, Emily Hassall, Marija Kojic, Caterina Brighi, Emily Girard, Clara Andradas, Mani Kuchibhotla, Dharmesh D. Bhuva, Raelene Endersby, Nicholas G. Gottardo, Anne Bernard, Christelle Adolphe, James M. Olson, Michael D. Taylor, Melissa J. Davis, Brandon J. Wainwright
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Genome Medicine
Subjects:
Medulloblastoma
Genetic screen
Protein interaction network
Drug target
Microtubule stabilization
Online Access:https://doi.org/10.1186/s13073-021-00920-z

Internet

https://doi.org/10.1186/s13073-021-00920-z

Similar Items